These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18757503)

  • 1. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.
    Henstridge CM; Balenga NA; Ford LA; Ross RA; Waldhoer M; Irving AJ
    FASEB J; 2009 Jan; 23(1):183-93. PubMed ID: 18757503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
    Obara Y; Ueno S; Yanagihata Y; Nakahata N
    PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
    Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
    J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
    Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
    J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway.
    Nakajima K; Oka S; Tanikawa T; Nemoto-Sasaki Y; Matsumoto N; Ishiguro H; Arata Y; Sugiura T; Yamashita A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
    Nevalainen T; Irving AJ
    Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
    Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
    Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
    Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells.
    Bondarenko A; Waldeck-Weiermair M; Naghdi S; Poteser M; Malli R; Graier WF
    Br J Pharmacol; 2010 Sep; 161(2):308-20. PubMed ID: 20735417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidylinositol-induced activation of the cation channel TRPV2 triggers glucagon-like peptide-1 secretion in enteroendocrine L cells.
    Harada K; Kitaguchi T; Kamiya T; Aung KH; Nakamura K; Ohta K; Tsuboi T
    J Biol Chem; 2017 Jun; 292(26):10855-10864. PubMed ID: 28533434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans.
    Liu B; Song S; Ruz-Maldonado I; Pingitore A; Huang GC; Baker D; Jones PM; Persaud SJ
    Diabetes Obes Metab; 2016 Dec; 18(12):1263-1273. PubMed ID: 27561953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55.
    Oka S; Toshida T; Maruyama K; Nakajima K; Yamashita A; Sugiura T
    J Biochem; 2009 Jan; 145(1):13-20. PubMed ID: 18845565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of GPR55 as a lysophosphatidylinositol receptor.
    Oka S; Nakajima K; Yamashita A; Kishimoto S; Sugiura T
    Biochem Biophys Res Commun; 2007 Nov; 362(4):928-34. PubMed ID: 17765871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.
    AlSuleimani YM; Hiley CR
    Br J Pharmacol; 2015 Jun; 172(12):3043-57. PubMed ID: 25652040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
    Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
    J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier.
    Leo LM; Familusi B; Hoang M; Smith R; Lindenau K; Sporici KT; Brailoiu E; Abood ME; Brailoiu GC
    Neuroscience; 2019 Aug; 414():88-98. PubMed ID: 31279825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of GPR55 in rat white adipose tissue and serum LPI by nutritional status, gestation, gender and pituitary factors.
    Imbernon M; Whyte L; Diaz-Arteaga A; Russell WR; Moreno NR; Vazquez MJ; Gonzalez CR; Díaz-Ruiz A; Lopez M; Malagón MM; Ross RA; Dieguez C; Nogueiras R
    Mol Cell Endocrinol; 2014 Mar; 383(1-2):159-69. PubMed ID: 24378736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
    Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
    J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPR55 ligands promote receptor coupling to multiple signalling pathways.
    Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ
    Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.